DMSO stock is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
By increasing farmers' incomes, this could reduce poverty. It would also open up area which farmers could use to diversify crops for household use. The World Bank claims to be part of the solution to malnutrition, asserting that countries can best break the cycle of poverty and malnutrition by building export-led economies, which give them the financial means to buy foodstuffs on the world market. Child malnutrition can worsen with food price inflation. The 2021 to 2023 food price surge is associated with higher rates of wasting among children under five years of age. A 10% increase in food prices is associated with a 2.7% to 4.3% rise in overall wasting and a 4.8 to 6.1 percent increase in severe wasting among children under five years of age.
Geranylgeraniol 18-hydroxylase (EC 1.14.14.146, GGOH-18-hydroxylase) is an enzyme with systematic name geranylgeraniol,NADPH:oxygen oxidoreductase (18-hydroxylating). It catalyses the following chemical reaction
=== Vinylic selenides === Vinylic selenides are organoselenium compounds that play a role in organic synthesis, especially in the development of convenient stereoselective routes to functionalized alkenes. Although various methods are mentioned for the preparation of vinylic selenides, a more useful procedure has centered on the nucleophilic or electrophilic organoselenium addition to terminal or internal alkynes. For example, the nucleophilic addition of selenophenol to alkynes affords, preferentially, the Z-vinylic selenides after longer reaction times at room temperature. The reaction is faster at a high temperature; however, the mixture of Z- and E-vinylic selenides was obtained in an almost 1:1 ratio. On the other hand, the adducts depend on the nature of the substituents at the triple bond. Conversely, vinylic selenides can be prepared by palladium-catalyzed hydroselenation of alkynes to afford the Markovnikov adduct in good yields. There are some limitations associated with the methodologies to prepare vinylic selenides illustrated above; the procedures described employ diorganoyl diselenides or selenophenol as starting materials, which are volatile and unstable and have an unpleasant odor. Also, the preparation of these compounds is complex.
Sources: en.wikipedia.org
Where legal standards do not exist, Alphabet, Facebook or Microsoft have largely been uncontrolled in privacy invasion, for instance, Gmail pioneering surveillance of emails for ads as its first business model, and Facebook abolishing service-user voting rights over changes to its privacy policies in 2012. There are no rights yet in EU law for service-users to vote for representatives on boards of big tech companies that take their data, or to have decision-rights over use of their data, in contrast to the rights of service-users of websites like Wikipedia.
In January 2023, US president Joe Biden invited Lula to meet him in Washington, D.C., in February 2023 following a phone conversation between them on the 2023 Brazilian Congress attack. White House press secretary Karine Jean-Pierre confirmed the meeting adding that it would address "U.S. support of Brazil's democracy and how the two countries can continue to work together to promote inclusion and democratic values in the region and around the world". Climate change, migration, economic development and security matters were also discussed. In February 2023, Lula and a delegation including his Foreign Affairs special advisor Celso Amorim, Foreign minister Mauro Vieira, Finance minister Fernando Haddad, Racial Equality minister Anielle Franco, Environment e Climate Justice minister Marina Silva travelled to the US. During the trip Lula met with US Senator Bernie Sanders, Democratic House Representatives Alexandria Ocasio-Cortez, Pramila Jayapal, Sheila Jackson Lee, Brad Sherman and Ro Khanna before he met with US president Joe Biden at the White House. On 10 February, at a meeting with American president Joe Biden, Lula proposed the creation of a group of negotiators made up of countries "not involved in the war" (either directly or indirectly, i.e.
==== Nicotinic acetylcholine receptor modulators ==== Bupropion (amfebutamone; Aplenzin; BVF-033; Elontril; Quomem; Wellbutrin; Zyban) – norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor negative allosteric modulator – smoking withdrawal Cytisinicline (cytisine; Desmoxan; Tabex) – nicotinic acetylcholine receptor agonist – smoking withdrawal Varenicline (Champix; Chantix; CP-526,555; CP-526555-18) – nicotinic acetylcholine receptor agonist – smoking withdrawal
=== Isolation === Muscimol can be extracted from the flesh of the Amanita muscaria by treatment with boiling water, followed by rapid cooling, and further treatment with a basic resin. This is washed with water, and eluted with acetic acid using column chromatography. The eluate is freeze dried, dissolved in water, and passed down a column of cellulose phosphate. A subsequent elution with ammonium hydroxide and recrystallization from alcohol results in pure muscimol. In instances where pure muscimol is not required, such as recreational or spiritual use, a crude extract is often prepared by simmering dried Amanita muscaria in water for 30 minutes.
Sources: en.wikipedia.org
The public entity was called Fisher Scientific International Inc., and based in Hampton, New Hampshire. Fisher Scientific Company remained in Pittsburgh as an operating subsidiary. In 1992, Fisher facilities were ISO-9000 certified. In the 1990s, Fisher, with partner Intertech Corporation of Atkinson, New Hampshire, set up a pharmaceutical testing and certification lab in Moscow, Russia, to serve with the Russian Federation's Ministry of Health and Medical Industry needs. Fisher acquired Eastman Kodak Company's organic-chemicals business and Janssen Chimica, forming Acros Organics. In August 2004, the company merged with Apogent Technologies Inc., a company engaged primarily in the manufacture and sale of laboratory products in the United States and other countries. In May 2006, Fisher Scientific and Thermo Electron announced that they would merge in a tax-free, stock-for-stock exchange. The merger closed on November 9, 2006, and the merged company is now called Thermo Fisher Scientific. The merger was valued at $12.8 billion.
== Selected publications == Góngora-Benítez M, Tulla-Puche J, Albericio F (2014). Multifaceted roles of disulfide bonds. Peptides as therapeutics. Chemical Reviews. doi:10.1021/Cr400031Z Subirós-Funosas R, Prohens R, Barbas R, El-Faham A, Albericio F (2010). Oxyma: an efficient additive for peptide synthesis to replace the benzotriazole-based HOBt and HOAt with a lower risk of explosion. Chemistry (Weinheim An Der Bergstrasse, Germany). doi:10.1002/Chem.200900614 Ruiz-Sanchis P, Savina SA, Albericio F, Álvarez M. Structure, bioactivity and synthesis of natural products with hexahydropyrrolo[2,3-b]indole. Chemistry (Weinheim An Der Bergstrasse, Germany). doi:10.1002/Chem.201001451 El-Faham A, Albericio F (2011). Peptide coupling reagents, more than a letter soup. Chemical Reviews. 111: 6557-602. doi:10.1021/Cr100048W Isidro-Llobet A, Alvarez M, Albericio F (2009). Amino acid-protecting groups. Chemical Reviews. doi:10.1021/Cr800323S Bruckdorfer T, Marder O, Albericio F (2004). From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future. Current Pharmaceutical Biotechnology. doi:10.2174/1389201043489620
When grown for opium production, the skin of the ripening pods of these poppies is scored by a sharp blade at a time carefully chosen so that rain, wind, and dew cannot spoil the exudation of white, milky latex, usually in the afternoon. Incisions are made while the pods are still raw, with no more than a slight yellow tint, and must be shallow to avoid penetrating hollow inner chambers or loculi while cutting into the lactiferous vessels. In the Indian Subcontinent, Afghanistan, Central Asia and Iran, the special tool used to make the incisions is called a nushtar or "nishtar" (from Persian, meaning a lancet) and carries three or four blades three millimeters apart, which are scored upward along the pod. Incisions are made three or four times at intervals of two to three days, and each time the "poppy tears", which dry to a sticky brown resin, are collected the following morning. One acre harvested in this way can produce three to five kilograms of raw opium. In the Soviet Union, pods were typically scored horizontally, and opium was collected three times, or else one or two collections were followed by isolation of opiates from the ripe capsules. Oil poppies, an alternative strain of P. somniferum, were also used for production of opiates from their capsules and stems. A traditional Chinese method of harvesting opium latex involved cutting off the heads and piercing them with a coarse needle then collecting the dried opium 24 to 48 hours later.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.